We feel energised by PM Modi's vision for vaccine industry: Adar Poonawalla

Poonawalla's remarks came after attending an interaction of Indian manufacturers of the Covid-19 vaccine with PM Modi

Adar Poonawalla, chief executive officer, Serum Institute of India
Adar Poonawalla, chief executive officer (CEO) of Serum Institute of India (Photo: PTI image)
ANI General News
2 min read Last Updated : Oct 23 2021 | 8:46 PM IST

Serum Institute India (SII) CEO Adar Poonawalla on Saturday thanked Prime Minister Narendra Modi and said that the vision he has laid down for the vaccine industry encourages and energises them.

Poonawalla's remarks came after attending an interaction of Indian manufacturers of the COVID-19 vaccine with PM Modi.

In a tweet, Poonawala said, "The vaccine industry and I, thank you, Prime Minister Narendra Modi Ji, for excellent interaction. We feel energised and encouraged by the vision you have laid out for the industry."

Speaking to the media after the interaction, Poonawala said, "India's achievement of 100 crore COVID-19 vaccinations is a milestone achievement. The vision of our Prime Minister Narendra Modi. We achieved this because the industries worked with the government of India."

He added, "In the interaction, we discussed how to take the industry forward to prepare for the future pandemics. We discussed to continue enhancing the capacity and other things which will support the vaccine production. We discussed how to be ahead of other countries in the vaccine production."

Union Health Minister Mansukh Mandaviya and Minister of State for Health Bharati Pravin Pawar were also present during the interaction.

The interaction comes days after the country crossed a milestone of administering 100 crore vaccinations.

As per the Ministry of Health and Family Welfare, with the administration of 68,48,417 vaccine doses in the last 24 hours, India's COVID-19 vaccination coverage has surpassed the 100 Crore mark to reach 101.30 Cr (1,01,30,28,411) as per provisional reports till 7 am today.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Oct 23 2021 | 8:46 PM IST

Next Story